Ketim Technologies Selected for AusBiotech Innovation Activation Program
Brisbane, Australia – April 3,2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, has been selected to join AusBiotech’s inaugural Innovation Activation Program, delivered as part of the Australian Government’s Industry Growth Program.
The program brings together 30 early-stage biotech, medtech, and diagnostics companies from across Australia, providing tailored mentoring, commercialisation support, and access to a powerful network of industry experts and thought leaders. Participants will benefit from specialised workshops, strategic guidance, and opportunities to engage with investors and collaborators within the AusBiotech community.
As part of the program, Dr. Clarissa Yates, CEO and Founder of Ketim Technologies, will attend national conferences, participate in targeted skill-building sessions, and gain access to mentors who will help accelerate the company’s mission to bring the world’s first clinical blood test for the early detection of postpartum depression to market.
“Being selected for the AusBiotech Innovation Activation Program is an incredible opportunity,” said Dr. Yates. “It connects us with Australia’s leading life sciences network and provides the tools and expertise we need to scale our innovation globally.”
The program kicked off in Brisbane with tours of the Translational Research Institute Australia and Thermo Fisher Scientific, followed by an intellectual property workshop featuring experts from FB Rice, Convergence Medical, and other industry leaders.
For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au
